Merck KGaA entrusts secretive startup with a mid-stage cancer drug targeting master signaling pathway

Kyle Blankenship

A secretive French biotech has imported a drug from Germany’s Merck KGaA that will leapfrog the small company right into mid-stage testing against cancer. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Merck KGaA entrusts secretive startup with a mid-stage cancer drug targeting master signaling pathway

Kyle Blankenship

Sign up to read this article for free.

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

Novartis to cut 139 jobs in NJ as part of commercial refocus

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

Recursion reduces workforce; Oxford Nanopore teams up with UK Biobank

Advanz Pharma faces revocation of European authorization for liver disease drug Ocaliva

Mer­ck KGaA en­trusts se­cre­tive start­up with a mid-stage can­cer drug tar­get­ing mas­ter sig­nal­ing path­way

Kyle Blankenship

Sign up to read this article for free.

more like this

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

Re­cur­sion re­duces work­force; Ox­ford Nanopore teams up with UK Biobank

Ad­vanz Phar­ma faces re­vo­ca­tion of Eu­ro­pean au­tho­riza­tion for liv­er dis­ease drug Ocali­va

Merck KGaA entrusts secretive startup with a mid-stage cancer drug targeting master signaling pathway

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

Novartis to cut 139 jobs in NJ as part of commercial refocus

To lead NIH, Trump taps Stanford academic and pandemic response critic Jay Bhattacharya

Recursion reduces workforce; Oxford Nanopore teams up with UK Biobank

Advanz Pharma faces revocation of European authorization for liver disease drug Ocaliva